TME Pharma Income Statement

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Other Revenue	-	-	-	-	0.03
Revenue	-	-	-	-	0.03
Revenue Growth (YoY)	-	-	-	-	-5.71%
Gross Profit	-	-	-	-	0.03
Selling, General & Admin	1.55	2.98	2.99	3.88	2.88
Research & Development	1.36	2.3	2.65	8.15	10.66
Other Operating Expenses	-0.05	-0.02	-0.02	-0.02	-0.04
Operating Expenses	2.86	5.26	5.62	12.01	13.49
Operating Income	-2.86	-5.26	-5.62	-12.01	-13.46
Interest Expense	-0.03	-0.02	-0.02	-0.13	-0.05
Currency Exchange Gain (Loss)	-0	0.01	0.01	-0.03	0.18
Other Non Operating Income (Expenses)	-0.39	-0.45	-1.34	-3.27	-1.42
EBT Excluding Unusual Items	-3.29	-5.72	-6.97	-15.45	-14.74
Other Unusual Items	-	-	0.24	0.32	0.29
Pretax Income	-3.29	-5.72	-6.73	-15.13	-14.45
Income Tax Expense	-	-	0	0.01	0
Earnings From Continuing Operations	-3.29	-5.72	-6.74	-15.13	-14.45
Minority Interest in Earnings	-	-	-	0	0
Net Income	-3.29	-5.72	-6.74	-15.13	-14.45
Net Income to Common	-3.29	-5.72	-6.74	-15.13	-14.45
Shares Outstanding (Basic)	94	36	5	1	1
Shares Outstanding (Diluted)	94	36	5	1	1
Shares Change (YoY)	161.66%	616.96%	326.62%	78.28%	103.92%
EPS (Basic)	-0.03	-0.16	-1.34	-12.86	-21.90
EPS (Diluted)	-0.03	-0.16	-1.34	-12.86	-21.90
Free Cash Flow	-3.42	-4.65	-5.65	-12.16	-12.4
Free Cash Flow Per Share	-0.04	-0.13	-1.13	-10.34	-18.79
Gross Margin	-	-	-	-	100.00%
Operating Margin	-	-	-	-	-40790.91%
Profit Margin	-	-	-	-	-43793.94%
Free Cash Flow Margin	-	-	-	-	-37560.61%
EBITDA	-2.84	-5.24	-5.59	-11.99	-13.44
D&A For EBITDA	0.02	0.02	0.03	0.02	0.02
EBIT	-2.86	-5.26	-5.62	-12.01	-13.46